摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[4-chloro-6-(3-methoxy-phenyl)-[1,3,5]triazin-2-ylamino]-phenol | 1189559-56-5

中文名称
——
中文别名
——
英文名称
4-[4-chloro-6-(3-methoxy-phenyl)-[1,3,5]triazin-2-ylamino]-phenol
英文别名
4-(4-Chloro-6-(3-methoxyphenyl)-1,3,5-triazin-2-ylamino)phenol;4-[[4-chloro-6-(3-methoxyphenyl)-1,3,5-triazin-2-yl]amino]phenol
4-[4-chloro-6-(3-methoxy-phenyl)-[1,3,5]triazin-2-ylamino]-phenol化学式
CAS
1189559-56-5
化学式
C16H13ClN4O2
mdl
——
分子量
328.758
InChiKey
OEDKPBPAOGYCPR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    23
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    80.2
  • 氢给体数:
    2
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS
    申请人:Wang Shudong
    公开号:US20110092490A1
    公开(公告)日:2011-04-21
    A compound of formula (I) and its pharmaceutically acceptable salts or solvates and physiologically hydrolysable, solubilising or immobilisable derivatives wherein: Ar is a 5-membered heteroaryl ring wherein X 1 and X 2 are one or two heteroatoms or Ar is a 6-membered aromatic ring, wherein heteroatoms are selected from S, O, N, Se; Z is NH, NHCO, NHSO 2 , N-alkyl, CH 2 NH, CH 2 N-alkyl, CH 2 , CH 2 CH 2 , CH═CH, CH 2 CONH, SO 2 , or SO; Y is N CR 3 ; R 1 , R 2 , R 5 , R 6 , R 7 , R 8 and R 9 are each independently H, or a substituent; R 3 , when present, is selected from alkyl and a substituent, with the proviso that when Y is CR 3 , Ar is a 5-membered heterocycle comprising one or two N heteroatoms and Z is NH, then R3 is selected from C 3+ alkyl and a substituent; R 4 is selected from H, alkyl and R 13 as hereinbefore defined, with the proviso that when R 3 is absent, R 4 is selected from alkyl and a substituent; processes for the preparation thereof, intermediates and precursors therefore and the use thereof as a medicament, and therapeutic compositions comprising the compound.
    化合物式(I)及其药学上可接受的盐或溶剂化合物和生理水解、溶解或固定化衍生物,其中:Ar是一个5元杂环芳基环,其中X1和X2是一个或两个杂原子,或Ar是一个6元芳香环,其中杂原子选自S、O、N、Se;Z是NH、NHCO、NHSO2、N-烷基、CH2NH、CH2N-烷基、CH2、CH2CH2、CH═CH、CH2CONH、SO2或SO;Y是N CR3;R1、R2、R5、R6、R7、R8和R9各自独立地为H或取代基;R3在存在时,选自烷基和取代基,但当Y为CR3,Ar为一个包含一个或两个N杂原子的5元杂环,并且Z为NH时,R3选自C3+烷基和取代基;R4选自H、烷基和如上所述的R13,但当R3不存在时,R4选自烷基和取代基;其制备方法、中间体和前体以及作为药物的用途和包含该化合物的治疗组合物。
  • [EN] PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS<br/>[FR] PYRIMIDINES, TRIAZINES ET LEUR UTILISATION EN TANT QU'AGENTS PHARMACEUTIQUES
    申请人:UNIV NOTTINGHAM
    公开号:WO2009118567A2
    公开(公告)日:2009-10-01
    A compound of formula (I) and its pharmaceutically acceptable salts or solvates and physiologically hydrolysable, solubilising or immobilisable derivatives wherein: Ar is a 5-membered heteroaryl ring wherein X1 and X2 are one or two heteroatoms or Ar is a 6-membered aromatic ring, wherein heteroatoms are selected from S, O, N, Se; Z is NH, NHCO, NHSO2, N-alkyl, CH2NH, CH2N-alkyl, CH2, CH2CH2, CH=CH, CH2CONH, SO2, or SO; Y is N or CR3; R1, R2, R5, R6, R7, R8 and R9 are each independently H, or a substituent; R3, when present, is selected from alkyl and a substituent, with the proviso that when Y is CR3, Ar is a 5- membered heterocycle comprising one or two N heteroatoms and Z is NH, then R3 is selected from C3+ alkyl and a substituent; R4 is selected from H, alkyl and R13 as hereinbefore defined, with the proviso that when R3 is absent, R4 is selected from alkyl and a substituent; processes for the preparation thereof, intermediates and precursors therefore and the use thereof as a medicament, and therapeutic compositions comprising the compound.
  • [EN] PYRIMIDINES, TRIAZINES AND THEIR USE AS KINASE INHIBITORS<br/>[FR] PYRIMIDINES, TRIAZINES ET LEUR UTILISATION EN TANT QU'AGENTS PHARMACEUTIQUES
    申请人:UNIV NOTTINGHAM
    公开号:WO2009118567A3
    公开(公告)日:2010-03-11
查看更多